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Haploinsufficiency of TAB2 Causes
Congenital Heart Defects in Humans
Bernard Thienpont,1,14 Litu Zhang,2,15 Alex V. Postma,3 Jeroen Breckpot,1 Le´on-Charles Tranchevent,4
Peter Van Loo,5,6 Kjeld Møllga˚rd,7 Niels Tommerup,2 Iben Bache,2 Zeynep Tu¨mer,2,8
Klaartje van Engelen,9 Bjo¨rn Menten,10 Geert Mortier,10,11 Darrel Waggoner,12 Marc Gewillig,13
Yves Moreau,4 Koen Devriendt,1 and Lars Allan Larsen2,*
Congenital heart defects (CHDs) are the most common major developmental anomalies and the most frequent cause for perinatal
mortality, but their etiology remains often obscure. We identiﬁed a locus for CHDs on 6q24-q25. Genotype-phenotype correlations
in 12 patients carrying a chromosomal deletion on 6q delineated a critical 850 kb region on 6q25.1 harboring ﬁve genes. Bioinformatics
prioritization of candidate genes in this locus for a role in CHDs identiﬁed the TGF-b-activated kinase 1/MAP3K7 binding protein 2 gene
(TAB2) as the top-ranking candidate gene. A role for this candidate gene in cardiac development was further supported by its conserved
expression in the developing human and zebraﬁsh heart. Moreover, a critical, dosage-sensitive role during development was demon-
strated by the cardiac defects observed upon titrated knockdown of tab2 expression in zebraﬁsh embryos. To deﬁnitively conﬁrm the
role of this candidate gene in CHDs, we performed mutation analysis of TAB2 in 402 patients with a CHD, which revealed two evolu-
tionarily conserved missense mutations. Finally, a balanced translocation was identiﬁed, cosegregating with familial CHD. Mapping of
the breakpoints demonstrated that this translocation disrupts TAB2. Taken together, these data clearly demonstrate a role for TAB2 in
human cardiac development.Introduction
Congenital heart defects (CHDs) are the single most impor-
tant congenital cause for perinatal mortality and mor-
bidity,1,2 but despite thismanifest importance, their etiology
remains largely obscure. Although epidemiological studies
demonstrated that certain environmental factors are con-
tributory,3 family and twin studies suggest a major genetic
component.4,5 Indeed,mutations in several geneswere asso-
ciatedwithmonogenicCHDs,mainly through linkage anal-
ysis in large families in which a CHD segregates as an auto-
somal-dominant trait.6 Given the mortality associated with
CHDs, such large families are rare. Although family studies
suggest that partially penetrant causes of CHDs are much
more common than purely monogenic causes,7,8 such loci
have remained unidentiﬁed in linkage studies. As a result,
only few causative geneshave been identiﬁed, andmutation
analyses have shown that they account for only a very small
fraction (< 1%) of CHD cases,9 representing a serious limita-
tion in the genetic counseling of CHD patients and their
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The AmeTo accommodate these limitations, we attempted an
alternative approach by identifying loci associated with
CHDs through chromosomal rearrangements. Such a strat-
egy enables the identiﬁcation of regions harboring genes
involved in heart development in a dosage-sensitive man-
ner and the construction of a human morbidity map for
CHDs. We previously reported the identiﬁcation of several
candidate loci for CHD through the screening of patients
with a CHD by means of array comparative genome
hybridization (aCGH).10,11 We describe here the delinea-
tion and characterization of one of these loci, located on
chromosome 6q24-q25 and containing the MAP3K7IP2
(TAB2 [MIM 605101]) gene. TAB2 maps to the critical
region deleted in patients with a CHD, is dosage-sensitive
in zebraﬁsh development, and is speciﬁcally expressed
in the human and zebraﬁsh cardiovascular system.
We moreover show that it is disrupted by a balanced trans-
location in three family members with a CHD and is
mutated in two out of 402 patients with CHDs, providing
strong evidence that TAB2 has a major role in cardiac
development.Genetics, University of Leuven, B3000 Leuven, Belgium; 2Wilhelm Johann-
Molecular Medicine, University of Copenhagen, DK-2200 Copenhagen,
ter, L2-108-2, Academic Medical Center Meibergdreef 15, 1105 AZ Amster-
ersity of Leuven, B3000 Leuven, Belgium; 5Department of Human Genetics,
d Developmental Genetics, VIB, B3000 Leuven, Belgium; 7Developmental
openhagen, DK-2200 Copenhagen, Denmark; 8Applied Human Molecular
diology and Clinical Genetics, Academic Medical Centre, 1105 AZ Amster-
pital, B9000 Ghent, Belgium; 11Department of Medical Genetics, Antwerp
partment of Pediatrics and Department of Genetics of the University of Chi-
tals Leuven, B3000 Leuven, Belgium
velopmental Genetics and Imprinting, Babraham Institute, Cambridge
gxi Medical University, 530000 Nanning, Guangxi, China
Genetics. All rights reserved.
rican Journal of Human Genetics 86, 839–849, June 11, 2010 839
Subjects and Methods
Patients
Informed consent was obtained from all patients or their legal
guardians for investigations on patient material and for anony-
mous publication. Syndromic CHD patients (Table S1, available
online) were followed by the Pediatric Cardiology Unit and the
Clinical Genetics Unit of the University Hospitals Leuven (patient
A), by the Clinical Genetics Unit of the Ghent University Hospital
(patient F), or as described (patients B, C, and I).12 Patients with
isolated CHDs (Table S2) were followed by the Pediatric Cardiology
Unit of the University Hospitals Leuven or collected from the
CONCOR national registry database and DNA bank.13 Patients
with CHD and a translocation were identiﬁed by systematic reex-
amination of carriers of balanced translocations.14 Patients with
isolated CHDs were not investigated by aCGH. These studies
were approved by the local ethics committees.Tissue Samples and Immunohistochemistry Analysis
Human embryonic tissues were collected from legal abortions.
Informed consent was obtained according to the Helsinki Declara-
tion II. Embryonic age was based on crown-rump length measure-
ment. Tissue samples were dissected into appropriate tissue blocks
and ﬁxed for 12–24 hr at 4C in 10%neutral buffered formalin, 4%
Formol-Calcium, or Lillie’s or Bouin’s ﬁxatives. The specimenswere
dehydratedwith graded alcohols, cleared in xylene, and embedded
in parafﬁn. Serial sections, 3–5 mm thick, were cut in transverse,
sagittal, or horizontal planes and placed on silanized slides.
Sections were deparafﬁnized and rehydrated in xylene followed
by a series of graded alcohols in accordance with established
procedures. The sections were treated with a fresh 0.5% solution
of hydrogen peroxide in methanol for 15 min for quenching of
endogenous peroxidase and were then rinsed in TRIS buffered
saline (TBS, 5 mM Tris-HCl, 146 mM NaCl, pH 7.6). Nonspeciﬁc
binding was inhibited by incubation for 30 min with blocking
buffer (ChemMate antibody diluent S2022, DakoCytomation,
Glostrup, Denmark) at room temperature. The sections were
then incubated overnight at 4Cwith a polyclonal rabbit antibody
which speciﬁcally recognizes human TAB2 (MAP3K7IP2), by
immunoblotting and immunohistochemistry (ARP32402, Aviva
Systems Biology, 1:1000) in blocking buffer (ChemMate antibody
diluent S2022, DakoCytomation).
The sections were washed with TBS and then incubated for
30 min with a peroxidase-labeled anti-rabbit polymer (DAKO
EnVision þ System/HRP K4011, DakoCytomation). The sections
were washed with TBS, followed by incubation for 10 min with
3,30-diamino-benzidine chromogen solution. Positive staining
was recognized as a brown color. The sections were dehydrated in
graded alcohols followed by xylene and coverslipped with DPX
mounting media. Nonimmune rabbit IgG1 (X0936) and staining
without primary antibody were used as negative controls. Sections
from human embryos containing osteoclasts served as positive
controls. Control sections stained without antibody or with
a nonimmune rabbit IgG1 were blank, whereas stained osteoclasts
were always positive.Molecular Cytogenetics
aCGH was performed as described15 on in-house-created microar-
ray slides, constructed with bacterial artiﬁcial chromosome (BAC)
or P1-derived artiﬁcial chromosome (PAC) probes chosen in
a genome-wide manner with 1 Mb spacing (set donated by the840 The American Journal of Human Genetics 86, 839–849, June 11,Sanger Institute) or chosen from chromosomes 6 and 2 with tiling
resolution (set obtained from BACPAC Chori, Oakland, CA, USA).
244K arrays were obtained from Agilent and hybridized according
to the manufacturer’s protocol. Genomic DNA was labeled by
the BioPrime Array CGH Genomic Labeling System (Invitrogen,
Carlsbad, CA, USA) with the use of Cy3- and Cy5-labeled dCTPs
(20-deoxycytidine 50-triphosphate) (Amersham Biosciences,
Boston, MA, USA) as recommended by the manufacturer with
minor modiﬁcations.15
Translocation breakpoints were mapped by ﬂuorescence in situ
hybridization (FISH) analysis with the use of 200 ng BAC DNA
according to standard procedures. The FISH signals were visualized
with an avidin-FITC detection system. Chromosomes were coun-
terstained with DAPI (4,6-diamino-2-phenylindole), and the
signals were investigated with a Leica DMRB epiﬂuorescence
microscope equipped with a Sensys 1400 CCD camera (Photomet-
rics, Tucson, AZ, USA) and IPLab Spectrum imaging software
(Abbott Laboratories, Abbott Park, IL, USA).Candidate-Gene Prioritization
Candidate-gene prioritization was performed with the use of an
adapted version of Endeavour.16 In brief, two data sources for
prioritization were added to the regular set of data sources: an
expression microarray data set of murine heart development
(GEO accession number GSE1479—transposed to human gene
identiﬁers with the use of BioMart) and a set representing gene
homology, extracted from HomoloGene, BioMart, and Inpara-
noid. These data were summarized by vector representations,
and scoring was done with the use of Pearson correlation. Addi-
tionally, prioritizations that were based on data sources displaying
strong Spearman rank correlation (> 0.3) were fused prior to fusing
with results from prioritizations based on more independent data
sources (Figure S1). Data sources were validated by leave-one-out
cross-validation (LOOCV) as described previously,16 and sources
with an area under the curve below 0.6 were omitted (Figure S2).
Genes were prioritized on the basis of seven training sets
(Table S5), representing discrete aspects of cardiac development
and genetics, and results from the seven sets were fused with the
use of rank-order statistics.16 In silico testing by LOOCV demon-
strated that this adapted algorithm readily ranks genes with an
established involvement in heart development, on average in
the top 5%. All 105 annotated protein-coding genes from 6q24-
q25 were prioritized. Gene identiﬁcation and prioritization was
based on Ensembl Release 49 and Endeavour databases of May
2008.Zebraﬁsh Assays
Wild-type (AB) or ﬂk-green ﬂuorescent protein (ﬂk-GFP)17 zebra-
ﬁsh (Danio rerio) stocks were maintained in accordance with stan-
dard aquaculture guidelines. Eggs were collected after natural
mating within 30 min after being laid so that timed development
was assured. RNA was extracted with TRIzol, and cDNA was
synthesized with random primers and the Superscript III kit (all
from Invitrogen, Merelbeke, Belgium).
Whole-mount in situ hybridizations (WISH) on wild-type and
ﬂk-GFP zebraﬁsh embryos was performed as described previ-
ously18 with the use of a sequence-veriﬁed probe ampliﬁed by
PCR from the synthesized cDNA. The resulting embryos were
imaged or embedded in acrylamide-bisacrylamide gel, cryosec-
tioned to 20 mm, and mounted on vectabond-pretreated micro-
scope slides. Sections were rehydrated in phosphate-buffered2010
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Figure 1. Fine Mapping of Chromosome
Aberrations in 6q24-q25, and Candidate-
Gene Prioritization
(A) Position of deletions found in patients
with a CHD (red bars) or without a CHD
(black bars). Deletion reference letters are
shown on the bars. Regions containing
deletion breakpoints are shown in gray.
Phenotypes shown as in Table S1. Deletion
F was found in a male and his mother,
both affected by CHDs. The critically
deleted region for CHDs is demarcated by
a light red box.
(B) Position of deletions found in the
region deleted in all CHD patients (com-
monly deleted region) with respect to the
11 annotated genes encoded in this
region. The deletion found in patient H
(black, no CHD) does not affect the TAB2
gene, and it demarcates the critically
deleted region, which contains ﬁve genes.
The arrow indicates the position of the
translocation breakpoint on chromosome
6 found in family N.saline with 0.1% Tween 20 (PBT) and incubated for 4 hr with PBT-
1% preimmune donkey serum (PDS) at room temperature and
then overnight at 4C with Alexa-647-labeled GFP antibody
(sc-9996 AF647 from Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1/200 in PBT-1% PDS). Slides were washed four times in
PBT, mounted on vectashield-DAPI, and imaged on an Olympus
FV1000 for confocal imaging and an Olympus AX51 for bright-
ﬁeld imaging.
Morpholinos (MOs) were designed against the intron 2-exon 3
splice site (50-ATC ACT CTT GTT CTG AGG AAA GAA G-3,
splice-site-blocking MO [sbMO]) and the translation initiation
site (50-ATC TGC TGG TTT CCC TGT GCC ATT C-30, translation-
blocking MO [tbMO]) of tab2. Both MOs and a control MO
(cMO) (50-CCT CTT ACC TCA GTT ACA ATT TAT A-30) were
ordered from Gene Tools (Philomath, OR, USA). Fidelity of anno-
tated nucleotide sequences of MO binding sites was conﬁrmed by
direct sequencing. MOs were diluted in a 1/50 Rhodamine solu-
tion, and an estimated 0.5 nL was injected at the one- or two-
cell stage at speciﬁed doses. tab2 mRNA concentrations were
measured by real-time quantitative (rtq) PCR as described previ-
ously15 and normalized to b-actin.Mutation Analysis
DNA was collected from patients with an outﬂow tract defect
(tetralogy of Fallot [ToF], pulmonic stenosis [PS], aortic stenosis
[AS]). Exons and exon-intron boundaries of TAB2 were ampliﬁed
by PCR with the use of oligonucleotide primers described in Table
S3. PCR products were sized by DNA gel electrophoresis and
sequenced with the BigDye DNA sequencing kit (Applied Biosys-
tems, Foster City, CA, USA).Results
We present the identiﬁcation and delineation of a locus for
CHDs, and we describe how a candidate gene was selected
from this locus. We investigated the role of this gene in
heart development through expression analyses and func-The Ametional studies, and we present the results of mutation
analysis.Molecular Characterization of Deletions in 6q24-q25
We observed deletions of 6q24-q25 in multiple syndromic
CHD patients. In the framework of an aCGH screening
study,4 aCGH on 1Mb arrays revealed the presence of
a 6q24.2-q25.1 deletion in patient A, shown to have
occurred de novo by rtqPCR analysis of parental DNA.
Patient A had an aortic coarctation, a hypoplastic aortic
arch, and a ventricular septal defect, as well as additional
problems. During a routine analysis of patients with an
unexplained syndromic disorder, a second deletion was
detected and delineated in patient Fp with the use of Agi-
lent 44K arrays. It was shown by rtqPCR to be inherited
from his mother (Fm). This mother (Fm) was diagnosed in
her childhood with aortic and mitral valve stenosis and
had episodes of sinus tachycardia. Our studies prompted
us to perform an echocardiographic evaluation of patient
Fp, which revealed mild centrovalvular insufﬁciency of
the aortic and pulmonary valves. Previously reported inter-
stitial 6q deletions (patients B, C, and I)12 were further
delineated by aCGH on 244K arrays. Genotype data on
other patients (D, E, G, H, J, and K) were collected from
literature reports12,19–23 or from an online database on car-
diogenetics, CHDWiki.24 The extent of all deletions and
the presence or absence of CHDs in deletion carriers is de-
picted in Figure 1A, and more detailed phenotype and
genotype data are provided in Table S1.
Cardiac defects identiﬁed in deletion patients mostly
affected the outﬂow tract. They included stenosis of one
or more heart valves, hypoplasia of the aortic arch, and
atrial or ventricular septal defects. Patients with larger dele-
tions typically also had amildmental retardation and addi-
tional congenital problems, whereas those with smallerrican Journal of Human Genetics 86, 839–849, June 11, 2010 841
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Figure 2. TAB2 Expression in Human Embryonic Hearts
(A) Section of a 5.5 wk embryo. TAB2 expression (brown color) is
prominent in the ventricular trabeculae and in the endocardial
cushions of the outﬂow tract.
(B) Magniﬁcation of endocardial cushions.
(C) Frontal section of a 7.5 wk embryo.
(D) Magniﬁcation showing cytoplasmic expression of TAB2 in the
endothelial cells lining the developing aortic valves.
Abbreviations are as follows: At, atrium; Ao, aorta; EC, endocardial
cushions; Tr, trabeculae; Ve, ventricle.Prioritization of Genes on 6q24-q25 for CHD
The clustering of CHD-associated deletions on 6q24-q25
suggested that haploinsufﬁciency of one or more genes
in this locus causes CHDs. Although this putative CHD
gene most likely resides in the commonly deleted region,
we could not exclude the alternative hypothesis that two
or more genes located elsewhere on 6q24-q25 cause
CHDs with incomplete penetrance. The in silico analysis
was therefore extended to all genes on 6q24-q25. In addi-
tion, this extension of our test set enabled a better assess-
ment of the statistical power of our ﬁndings. Gene prioriti-
zation yielded a ranked list of candidate genes for CHDs,
with MAP3K7IP2 (also known as TAB2) ranking ﬁrst of all
105 genes from 6q24-q25 (Table S4 and Figure S3). The cor-
responding p value (4.17 3 107) was highly signiﬁcant; it
is located in the critically deleted region, and no signiﬁcant
prioritization (p< 0.01) was obtained for any other gene in
the commonly deleted region. Upon genome-wide prioriti-
zation, TAB2 moreover ranks 44th among all genes of the
human genome (Table S6). It thus seemed like a likely
candidate gene for CHDs.TAB2 Expression in Human Embryonic Hearts
To explore the potential role of the TAB2 candidate gene in
human heart development, we analyzed its expression in
human embryos. Immunohistochemistry analysis of tissue
sections from 5.5 wk and 7.5 wk human embryos showed
cytoplasmic expression of TAB2 in cells of the ventricular
trabeculae (Figure 2A), in endothelial cells of the conotrun-
cal cushions of the outﬂow tract (Figures 2A and 2B), and
in the endothelial cells lining the developing aortic valves
(Figures 2C and 2D). These results indicate a function of
TAB2 in the developing human heart.tab2 Zebraﬁsh Assays
We used zebraﬁsh as a model organism to investigate the
role and dosage sensitivity of tab2 during vertebrate devel-
opment. WISH on staged wild-type zebraﬁsh embryos
revealed ubiquitous tab2 expression during early devel-
opment (12–18 hr postfertilization [hpf]) and a more
restricted expression pattern during later development,
with expression in the developing cardiac outﬂow tract,
the dorsal aorta, and the posterior cardinal vein (Figure 3).
This expression pattern is reminiscent of the expression
during human heart development and thus suggests
a conserved role for tab2 in the cardiac outﬂow tract.842 The American Journal of Human Genetics 86, 839–849, June 11,To investigate the function of tab2 during zebraﬁsh
development, we knocked down its expression by using
two independent MOs that were interfering with either
normal splicing or translation of the tab2 RNA. Injection
of either resulted in similar developmental abnormalities,
whereas injection of the same amount of cMO did not
result in abnormal development. Knockdown was thus
demonstrated to be speciﬁc. The ﬁrst embryological defects
became apparent during gastrulation (Figures 4F and 4G)
and included delayed epiboly progression and convergent
extension defects. Later in development (36–48 hpf),
severe heart failure became apparent (Figures 4D and 4E):
the heart tube appeared thin and elongated, with blood
pooling in the common cardinal vein before entry into
the heart.
The molecular effect of sbMO injection on splicing of
nascent tab2 RNA was investigated by PCR on cDNA
from injected embryos (Figure 4B). Sequencing of RT-PCR
products revealed that a transcript lacking wild-type exon
3was formed upon this treatment, resulting in a frameshift
and a premature stop codon starting at the seventh nucle-
otide of wild-type exon 4 (Figure 4A). This sbMO-generated
transcript thus encodes a 95% truncated variant of the
normal protein. As conﬁrmed by the similar phenotype
observed upon tbMO injection, this represents a loss-
of-function situation. The relative amount of correctly
spliced mRNA was assessed by rtqPCR on cDNA reverse2010
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Figure 3. Gene Expression of tab2 in the Developing Zebrafish
mRNA expression of tab2 in the developing zebraﬁsh at distinct developmental stages (indicated in the lower left corner). Boxed parts of
embryos at 30 hpf and 55 hpf are repeated in (A) and (C00 0), respectively.
(A): Magniﬁcation showing expression of tab2 in the dorsal aorta (arrow) and posterior cardinal vein (arrowhead).
(B) Transverse section through the hindbody of a zebraﬁsh at 30 hpf depicted in (A), showing restricted expression in the dorsal aorta
(arrowhead) and posterior cardinal vein (arrow).
(C): Bright-ﬁeld image of the expression of tab2 in the cardiac outﬂow tract at 55 hpf (arrow).
(C0) DAPI staining of the section depicted in (C) (pseudocolored in blue).
(C00) The section depicted in (C), immunostained with Alexa-647-labeled GFP antibody (pseudocolored in red), displaying the position of
the cardiac outﬂow tract (arrow).
(C00 0) Image of a 55 hpf, whole-mount-stained embryo, presenting the orientation of the section shown in (C), (C0), and (C00) (white line).transcribed from RNA that was extracted from sbMO-
injected embryos at 20 hpf. This revealed that sbMO injec-
tion resulted in a dose-dependent reduction of normal
splicing (Figure 4C). Phenotypes became apparent at a dose
of 2 to 3 ng, corresponding to a 41% to 58% reduction of
normal expression, thus showing that haploinsufﬁciency
of tab2 causes developmental defects (Figures 4C–4I).Sequence Analysis of TAB2 in Human Patients
with Outﬂow Tract Defects
Because TAB2 has a relevant spatiotemporal expression
pattern and a dosage-sensitive role in development, it
was a very good candidate gene for explaining the CHDs
evident upon deletion of 6q24-q25. To further conﬁrm
the role of TAB2 in CHDs, we analyzed the DNA sequence
of TAB2 in 402 patients with outﬂow tract defects
(Table S2). These patients were not analyzed by aCGH.
Sequencing analysis revealed two heterozygous missense
mutations in the TAB2 gene. One female (patient L) carried
a c.622C>T mutation, causing a p.Pro208Ser mutation
at the protein level (Figures 5A and 5C). She had a left-
ventricular outﬂow tract obstruction, a subaortic stenosis
(subAS) due to a ﬁbromuscular shelf, residual aortic regur-
gitation, and atrial ﬁbrillation and died at 61 years of age
because of heart failure. Patient M carried a c.688C>A
mutation, causing a p.Gln230Lys mutation at the protein
level (Figure 5B). He had a bicuspid aortic valve and an
aortic dilation. Both mutations alter highly conserved resi-
dues and are predicted to have detrimental effects onThe Ameprotein function (Figure 5C). Neither DNA samples nor
phenotypic data were available for family members of
patients L or M. These mutations were, however, absent
from 658 ethnically matched control chromosomes.Investigation of a Family with a t(2;6) Translocation
and CHD
A family with CHD segregating with a t(2;6)(q21;q25)
translocation was previously identiﬁed.14 In this family
(family N), all three translocation carriers have a history
of CHD (Figure 5D). Patient N-II.2 was diagnosed with
aortic stenosis and atrial ﬁbrillation at age 67 and required
an aortic valve replacement. Patient N-III.1 was diagnosed
with aortic stenosis at the age of 2 yrs. Her aortic valve was
surgically replaced at age 25. At age 34 she was hospitalized
for paroxysmal supraventricular tachycardia. She died at
age 49 from a myocardial infarction. Patient N-III.2 was
diagnosed— like his mother and sister—with cardiac
rhythm problems (sick sinus syndrome, tachycardia).
However, he refused to participate in further clinical exam-
inations and was not investigated by echocardiography.
The translocation segregating in this family was bal-
anced, as demonstrated by aCGH on 1Mb arrays and on
chromosome 6 and 2 tiling microarrays (data not shown).
FISH studies positioned the translocation breakpoint
on 2q21 to a 14.2 kb region at chromosome position
131,691,033-131,705,253, disrupting the POTEE gene
(encoding prostate, ovary, testis-expressed protein E).
The position of the translocation breakpoint in 6q25rican Journal of Human Genetics 86, 839–849, June 11, 2010 843
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Figure 4. tab2 Knockdown in Zebrafish
(A) Schematic organization of the tab2 gene in the zebraﬁsh genome. Two alternative splice isoforms as detected by PCR on the reverse-
transcribedmRNA are shown. Introns are dotted lines, exons full boxes (coding sequences in black, noncoding sequences in orange). The
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Figure 5. TAB2 Is Mutated and Disrupted in CHD Patients
(A and B) Partial TAB2 reference-sequence-read traces and corresponding traces of missense mutations as identiﬁed in patients L and M
(phenotypes detailed in the main text).
(C) Conservation of mutated residues in several tetrapod and ﬁsh lineages. TAB2 is not found in lower lineages; the mutated residues are
not conserved in the paralogous TAB3.
(D) Pedigree of family N. Translocation carriers are marked, and the breakpoint on chromosome 6 disrupts TAB2. Phenotypes are as
annotated in the insert and are detailed in the main text.lies within a 17 kb region at chromosome position
149,678,240-149,695,219, within the ﬁrst intron, ﬁrst
exon, or promoter region of TAB2 (Figure S4).Discussion
We identiﬁed a locus for CHDs on 6q24-q25, which is
deleted in seven individuals with a CHD (Figure 1A). In
search of genes causing the CHDs in this region, we prior-
itized all 105 genes from chromosome 6q24 and 6q25 for
their involvement in heart development, using a tool
based on an established genomic data fusion algorithm.16
This strategy ensures gene selection that is inﬂuenced
to only a minor extent by a researcher’s prior knowledgetarget sites of the sbMO) and tbMO are indicated by double arrowhea
mature tab2 mRNA (isoforms 1 and 2).
(B) Gel electrophoresis of the product of PCR on cDNA extracted fro
24 hpf and a DNA marker for size comparison, showing one band ar
ments in the morphant situation.
(C) Effect of TAB2 sbMO injection on the amount of correctly splice
(D) Wild-type AB embryo at 48 hpf.
(D0) Noninjected embryo at 48 hpf expressing GFP in vascular endo
(E) Morphant embryo at 48 hpf. Note the enlarged pericardial sac (a
(E0) Morphant ﬂk-GFP embryo at 48 hpf. Note the thin and elongate
(F) Phenotypical classiﬁcation of sbMO-injected zebraﬁsh embryos at
of the yolk-syncytial layer is schematically displayed below. Phenoty
gradient is not evident. Class II: the yolk-syncytial layer has not pr
to illustrate the continuum in phenotypes in class II. Class III: wild-
(G) Distribution of phenotypes at 12 hpf dependent upon the sbMO
cated by the color code. X axis: amount of TAB2 sbMO injected at th
each dose. In total, over 230 embryos were successfully injected.
(H) Phenotypical classiﬁcation of sbMO-injected zebraﬁsh embryos
death. Other classes are as described in the main text. Lateral images
(I) Distribution of phenotypes at 24 hpf dependent upon the sbMO
amount of TAB2 sbMO injected at the one-cell stage. At least 42
230 embryos were successfully injected. Injection of 4 ng of cMO did
to noninjected or 0 ng-injected control embryos (not shown).
The Ameand preferences. TAB2 ranked ﬁrst (p ¼ 4.17 3 107)
among all candidate genes (Figure 1C). Importantly,
none of the other ten genes in the commonly deleted
region generated a signiﬁcant signal for their involvement
in heart development with the use of this method (p >
0.03 for all).
Support for the involvement of TAB2 in human heart
development was further provided by the expression of
this gene in developing human and zebraﬁsh embryos.
TAB2 is expressed in the endothelial lining of the devel-
oping human heart: we detected expression in endothelial
cells lining the trabeculae and the developing aortic valves
(Figure 2). Endocardial cushions are involved in endothe-
lial-mesenchymal transformation, an important event
during development of the cardiac valves and outﬂowds. The lower schema indicates the effect of sbMO injection on the
m nonmorphant (WT) or 2 ng sbMO-injected zebraﬁsh embryos
ound 2000 bp in the wild-type situation, and two additional frag-
d mRNA.
thelial cells under the inﬂuence of an ﬂk promoter (ﬂk-GFP).
rrow).
d heart.
12 hpf. Defects in epiboly progression are evident, and progression
pes are ordered from severe to normal. Class I: anterior-posterior
ogresses until the vegetal pole; two different embryos are shown
type. Left, posterior; up, dorsal.
dose injected. Y axis: percentage of embryos in each class as indi-
e one-cell stage. At least 42 embryos were successfully injected for
at 24 hpf. Phenotypes are ordered from severe to normal. Class I:
: up, anterior.
dose injected. Y axis: percentage of embryos in this class. X axis:
embryos were successfully injected for each dose. In total, over
not increase the frequency of abnormal phenotypes in comparison
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tract.25 The conservation of Tab2 expression in the devel-
oping cardiovascular system of the mouse26 and the zebra-
ﬁsh (Figure 3) further supports the functional relevance of
TAB2 in cardiovascular development.
TAB2 (TAK1 binding protein 2) encodes a protein that is
studied mainly for its role in the inﬂammatory response.
TAB2 causes autophosphorylation and activation of
mitogen-activated protein kinase kinase kinase 7 (MAP3K7,
also known as TAK1 [MIM602614]),27 thus (throughmedia-
tors such as TNF-receptor-associated factors [TRAFs] and
receptor-interacting proteins [RIPs]) relaying signals from
receptors for chemokines (TNF, LPS, IL1) and other extracel-
lular signaling molecules (TGF-b and Wnt) to downstream
proteins suchas IKK,p38, JNK,RCAN,andNLK.TAK1conse-
quently modulates the activity of molecules such as NF-kB,
b-catenin, NFAT, and HDAC3 and their downstream target
genes. Tak1/ mice die around embryonic day 10.5
(E10.5) to E12.5 and have neural tube and cardiovascular
defects.28,29 Xie and colleagues (2006)30 generated mice
with a cardiac-speciﬁc expression of a dominant-negative
Tak1, showing that inhibiting Tak1 function in the heart
leads toalteredelectrical conduction (shortenedPR interval),
impaired ventricular ﬁlling, and cardiac hyperthropy. Inter-
estingly, the authors also discussed unpublished results that
showed that cardiac-speciﬁc deletion of Tak1 causesmidges-
tation death.30 Zhang and colleagues (2000)31 reported on
mice with cardiac-speciﬁc expression of activated Tak1,
showing that they develop cardiac hypertrophy. Combined,
these results demonstrate that altered Tak1 signaling in the
heart leads to cardiac disorders. Of interest, in our aCGH
screening study that led to the identiﬁcationof thepresented
TAB2 deletion, we identiﬁed a 650 kb TAK1 duplication in
a girl with a pulmonary stenosis (data not shown). This
duplication was inherited from her mother, who has no
cardiac defect. Her brother had died early in childhood
from a severe pulmonary valve stenosis as well, but no
DNAwas available for study.
Tab2/ mice die around E12.5 and display severe liver
degeneration with increased hepatocyte apoptosis. No
immunological or hematological problems were described
in patients with TAB2 disruption. Interestingly, however,
70% of Tab2þ/ mice die within 1 wk after birth. The
reason for this increased mortality was not established.32
Although this obviously precludes a direct phenotypic
comparison with human hemizygous patients, it does
demonstrate that Tab2 is dosage sensitive in the mouse
and is an excellent candidate for explaining the CHDs
observed in the patients.
To further investigate the dosage sensitivity of tab2, we
titrated a knockdown of tab2 gene expression through
MO injection. We observed phenotypic changes when
the fraction of normal tab2 mRNA approximately halved,
demonstrating that the tab2 gene is dosage sensitive also
in the zebraﬁsh. The morphants displayed early embryo-
logical defects (delayed epibolic movements during gastru-
lation; Figure 4F) and further developed into larvae that
were shorter and had a dysfunctional heart, a curved tail,846 The American Journal of Human Genetics 86, 839–849, June 11,abnormal somites, and a small head in comparison to
control larvae. However, the early defects observed in these
embryos preclude a conclusive analysis on the involve-
ment of tab2 in heart development: although the hearts
of morphant embryos were abnormally structured and
heart failure was evident by the enlarged pericardial sac
(Figure 4E), we cannot exclude that these effect are sec-
ondary to the earlier defects in gastrulation. Other reports
have similarly shown that knockout of genes involved in
isolated CHDs in humans can cause a much more pleio-
tropic phenotype in zebraﬁsh.33 This is probably attribut-
able to species-speciﬁc differences; for example, in the
epibolic movements that have no direct correlate in
mammalian development. Nevertheless, the clear dosage
sensitivity of tab2 in zebraﬁsh again demonstrates that
a proper tab2 dosage is critical for a normal development
in vertebrates.
Because of the above ﬁndings and for conﬁrmation of
the role of TAB2 in CHD, we investigated the presence of
germline mutations in CHD patients. This revealed two
missense mutations affecting evolutionarily highly con-
served residues (Figures 5A–5C). These conserved residues
arenot inany recognizedproteindomain,nordo theyaffect
any of the hitherto described protein binding sites; future
studies will need to establish the function of this conserved
domain. The observed paucity in mutations was not unex-
pected given the known etiological and genetic heteroge-
neityofCHDs:mutations inothergeneswithanestablished
role inCHDdevelopment are similarly found inonly a small
(<1%) fraction ofCHDpatients.9 Furthermore, becausenot
all CHD phenotypes were investigated, we cannot exclude
that TAB2 mutations are associated with additional CHD
phenotypes. Moreover, we identiﬁed a family in which
CHD and cardiomyopathy cosegregate with a balanced
translocation between 2q21 and 6q25. Family members
that do not carry this translocation do not have a CHD.
Thebreakpoint in2q21disrupts thePOTEEgene (Figure S4),
one of seven poorly conserved paralogues of a recently
expanded gene family.34 Given that these genes are not
expressed in the mammalian heart and that POTEE is vari-
able in copy number in the normal human population, it
is unlikely that disruption of POTEE causes the observed
CHDs in this family. The breakpoint on 6q25 is located
withinTAB2, which leads to its disruption, further support-
ing a role for TAB2 in the pathogenesis of CHD. Taken
together, these results demonstrate that perturbations and
mutations of TAB2 are indeed causing CHDs.
Although most of the described CHDs are outﬂow tract
defects, we do not exclude that the phenotypic spectrum
extends further. Indeed, patient C presented with an atrial
septum defect (ASD) and patient E with a ventricular septal
defect (VSD) (Table S1). This is not surprising, given
the large variation in CHD phenotypes that has been
described in most genetic syndromes. A classic example
is 22q11 deletion syndrome, in which CHD phenotypes
include Tetralogy of Fallot (ToF), pulmonary stenosis (PS),
interrupted aortic arch, VSD, ASD, and other cardiac2010
malformations.35 Other examples includeWolf-Hirchhorn
syndrome, in which patients may have ASD, PS, VSD, or
patent ductus arteriosus,36 and Smith-Magenis syndrome,
in which valvular abnormalities, ASD, VSD, and ToF
have been reported.37 Variable CHD phenotypes are also
observed in patients with gene mutations. Examples are
plenty and include patients with JAG1 mutations, in
which PS, aortic stenosis, VSD, and ASD have been re-
ported,38 and patients with CITED2 mutations, who can
present with ASD, VSD, ToF, or transposition of the great
arteries.39 Patients with NOTCH1 mutations can present
with AS, VSD, ToF, or a double outlet right ventricle, but
they are also at risk for late-onset complications such as
aortic valve calciﬁcation and AS, requiring valve replace-
ment,40 as was observed in patient N-II.3.
In conclusion, we demonstrated the ability of a posi-
tional cloning strategy for the identiﬁcation of genes
involved in human heart defects. The strategy presented
here enables a rapid, generic, and powerful positional
cloning and led to the identiﬁcation of a gene involved
in CHD, TAB2. This gene is expressed in the developing
heart, is dosage sensitive in zebraﬁsh development, and
is mutated, deleted, or disrupted by a translocation in
CHD patients.
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